Biofarma v. Bal Pharma Limited

In the fiercely competitive pharmaceutical industry, brand names are often treated like crown jewels. But what happens when a company tries to claim ownership over a tiny, three-letter abbreviation that simply describes what the drug actually does? The Delhi High Court faced exactly this question in a dispute that serves as a sharp reminder for every founder building a brand in the healthcare space: not every word you use can be yours alone.

Biofarma, the plaintiff, had built a pharmaceutical product around the term 'MEX.' When Bal Pharma Limited, the defendant, began marketing a similar product using the same 'MEX' mark, Biofarma swung into legal action. The plaintiff alleged that Bal Pharma was guilty of passing off and trade dress infringement, arguing that 'MEX' was its established brand and that the rival's use of it would confuse customers and dilute Biofarma's hard-earned reputation in the market. The dispute landed before the Delhi High Court on 22 November 2018, putting the spotlight on a fundamental question of trademark law in the pharmaceutical sector.

Biofarma argued that 'MEX' was its proprietary mark, closely associated with its product, and that Bal Pharma's adoption of the same term amounted to unfair competition and infringement of its trade dress. The company positioned itself as the rightful owner of the brand identity built around the abbreviation. Bal Pharma, on the other hand, countered that 'MEX' was not a fanciful invention but a descriptive acronym standing for 'Metformin Extended Release' — a direct reference to the principal active ingredient and the formulation type of the drug itself. The defendant argued that such a term was descriptive in nature and belonged to the public domain, meaning no single company could monopolize it.

The Delhi High Court sided with Bal Pharma and dismissed Biofarma's suit. The court reasoned that 'MEX' was an acronym derived directly from the drug's principal ingredient — 'Metformin Extended Release' — making it descriptive and publici juris, a term belonging to the common trade rather than any individual proprietor. Because the abbreviation was rooted in the inherent nature of the pharmaceutical product itself, Biofarma could not claim exclusive rights over it. The court held that allowing one company to monopolize such a descriptive term would unfairly block competitors from accurately describing their own formulations. As a result, Bal Pharma was permitted to continue using the 'MEX' mark without any finding of infringement or passing off.

For founders and IP professionals in the pharmaceutical sector, this case delivers a clear and practical lesson: descriptive abbreviations or terms that directly reference a drug's active ingredient or formulation type generally fall into the public domain and cannot be monopolized as trademarks. When building a brand around a pharmaceutical product, invest in distinctive, fanciful, or arbitrary marks rather than acronyms that merely describe what the drug does. Otherwise, you risk investing heavily in brand equity around a name that the law will ultimately consider free for any competitor to use.